Emerging knee OA therapies: review map

A 2026 narrative review maps a wider knee osteoarthritis pipeline, from symptom treatments to candidates intended to alter joint biology. The paper reports no new trial participants or pooled effect estimate. Its clearest peptide-related conclusion is that semaglutide is the first incretin-based therapy to show substantial pain and function benefits, while locally administered GLP-1 receptor agonists remain experimental^[1].

The review treats knee OA as heterogeneous

Courties and colleagues describe knee osteoarthritis as a whole-joint disease involving biomechanical, metabolic, inflammatory, osteochondral and neurovascular mechanisms. This heterogeneity helps explain why standard analgesics often produce modest relief and why attempts to develop disease-modifying osteoarthritis drugs have repeatedly struggled^[2]. A therapy aimed at one pathway may fit only a subset of patients, while pain can persist through several mechanisms at once.

The article is indexed as a review, and its abstract does not describe a systematic search, screening process or quantitative synthesis. That limits what can be inferred about comparative effectiveness. The authors organize an emerging field and identify signals worth testing. They do not rank treatments through a common evidence standard, and the abstract does not provide sample sizes or effect estimates for most candidates.

Symptom strategies span several mechanisms

The symptomatic pipeline includes incretin-based therapies, neurotrophin modulation, extended-release injections into the joint, lubricating injectables and image-guided neurovascular interventions. The review singles out semaglutide as the first incretin therapy to show substantial benefits for pain and function^[1]. That statement refers to previously published evidence rather than a new analysis performed by the review authors.

The main randomized semaglutide evidence is STEP 9, a 68-week double-blind trial in 407 adults with obesity and moderate knee osteoarthritis. Semaglutide plus lifestyle counseling produced a mean 13.7% weight reduction versus 3.2% with placebo, while WOMAC pain scores improved by 41.7 points versus 27.5 points. Physical function also improved more with semaglutide^[3]. Those results apply to adults with obesity and the trial's eligibility criteria. They do not establish the same effect in every knee osteoarthritis phenotype.

Disease modification remains a higher bar

Pain relief and structural disease modification are different claims. A patient can hurt less without measurable cartilage repair or slower joint deterioration. The review separates emerging symptomatic treatments from candidates intended to influence cartilage formation, Wnt signaling, matrix-degrading enzymes, bone beneath the cartilage, immunometabolic pathways or local gene expression. That distinction should remain visible when early findings are discussed.

Several candidates have encouraging signals, according to the review. These include locally administered GLP-1 receptor agonists, the anabolic agent TPX-100 and intra-articular IL-1 receptor antagonist gene therapy. The abstract provides no effect sizes, phase-specific details or long-term safety results for those approaches^[2]. An encouraging signal can justify a larger trial, but it does not establish clinical benefit or regulatory readiness.

Cell therapies show why product details matter

Mesenchymal stromal cell therapies have produced inconsistent efficacy across phase 3 trials, the authors report. They call for more standardization of cell products and better patient selection^[1]. The category label alone therefore says little. Manufacturing, cell characteristics, administration and eligibility can differ enough that one product's result should not be transferred to another.

This product-specific problem extends across the pipeline. Local injection and systemic treatment expose patients differently. A target supported by laboratory biology can fail when tested against pain or function in a varied clinical population. Trials also need endpoints matched to the intended claim: symptom scores for relief, imaging or validated biomarkers for structure, and sufficient follow-up to show whether any change lasts.

Commercial ties belong in the interpretation

The PubMed record includes extensive competing-interest disclosures. Authors reported consulting, speaking or advisory relationships with several pharmaceutical and biotechnology companies. One author holds patents, owns stock and co-founded a company developing an intra-articular GLP-1 agonist. These disclosures do not invalidate the review, but they matter because the paper interprets early-stage products and future therapeutic directions rather than reporting one preregistered trial outcome.

Readers should use the review as a map for locating the underlying studies. Any claim about a named candidate still needs confirmation from that candidate's trial record, methods and results. Evidence strength will vary sharply across an approved systemic medicine studied in a phase 3 randomized trial, an experimental local injection and a gene therapy with early clinical data.

What this review can support

The defensible conclusion is that knee osteoarthritis research is broadening beyond short-acting analgesia. Semaglutide has randomized evidence for weight, pain and function outcomes in adults with obesity and knee osteoarthritis. Several other approaches target symptoms or proposed disease mechanisms, but the review abstract does not establish comparable efficacy among them. Structural modification, durable safety and patient selection remain open questions for much of the pipeline.

The semaglutide evidence page provides broader molecule context. This review should not be read as a treatment menu or a reason to seek an experimental injection. Decisions about established care require a qualified healthcare professional, while investigational therapies belong in regulated research with clear consent and follow-up. The evidence remains specific to each product and study population. The next useful readouts will need to show which patients benefit, whether joints change structurally and whether any gains persist.